Merck CDR (CAD Hedged)

Healthcare CA MRK

25.84CAD
0.16(0.62%)

Last update at 2026-06-22T19:51:00Z

Day Range

25.7325.84

LowHigh

52 Week Range

16.3728.11

LowHigh

Fundamentals

Previous Close 25.68
Market Cap296286.70M
Volume454
P/E Ratio15.70
Dividend Yield12.32%
Revenue TTM0.00000M
Revenue Per Share TTM-
Gross Profit TTM 0.00000M
Diluted EPS TTM-

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Type	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Income before tax	21067.00M	19936.00M	1889.00M	16444.00M
Minority interest	-	-	-	-
Net income	18254.00M	17117.00M	365.00M	14519.00M
Selling general administrative	10610.00M	10733.00M	10382.00M	9948.00M
Selling and marketing expenses	-	-	-	-
Gross profit	52984.00M	49470.00M	44200.00M	42077.00M
Reconciled depreciation	-	-	-	-
Ebit	-	-	-	-
Ebitda	-	-	-	-
Depreciation and amortization	-	-	-	-
Non operating income net other	-	-	-	-
Operating income	21221.00M	19912.00M	1782.50M	17945.00M
Other operating expenses	-	-	-	-
Interest expense	-	-	-	-
Tax provision	2804.00M	2803.00M	1512.00M	1918.00M
Interest income	-663.00000M	1069.00M	811.00M	2461.00M
Net interest income	-	-	-	-
Extraordinary items	-	-	0.00000M	0.00000M
Non recurring	-	-	-	-
Other items	-	-	-	-
Income tax expense	-	-	-	-
Total revenue	65011.00M	64168.00M	60115.00M	59283.00M
Total operating expenses	43790.00M	44256.00M	58332.50M	41338.00M
Cost of revenue	12027.00M	14698.00M	15915.00M	17206.00M
Total other income expense net	-	-	-	-
Discontinued operations	-	-	-	-
Net income from continuing ops	-	-	-	-
Net income applicable to common shares	18254.00M	17117.00M	365.00M	14519.00M
Preferred stock and other adjustments	-	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Type	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total assets	136866.00M	117106.00M	106675.00M	109160.00M
Intangible assets	26681.00M	16370.00M	18011.00M	20269.00M
Earning assets	-	-	-	-
Other current assets	10518.00M	7865.00M	7645.00M	6509.00M
Total liab	84204.00M	70793.00M	69094.00M	63169.00M
Total stockholder equity	52606.00M	46313.00M	37581.00M	45991.00M
Deferred long term liab	-	-	-	-
Other current liab	-	-	-	-
Common stock	-	1788.00M	1788.00M	1788.00M
Capital stock	1788.00M	-	-	-
Retained earnings	73075.00M	63069.00M	53895.00M	61081.00M
Other liab	-	-	-	-
Good will	21579.00M	21668.00M	21197.00M	21204.00M
Other assets	-	13544.00M	9310.00M	6752.00M
Cash	14565.00M	-	-	-
Cash and equivalents	-	13242.00M	6841.00M	12694.00M
Total current liabilities	28327.00M	28420.00M	25694.00M	24239.00M
Current deferred revenue	-	-	-	-
Net debt	34774.00M	-	-	-
Short term debt	-	0.00000M	0.00000M	0.00000M
Short long term debt	2589.00M	-	-	-
Short long term debt total	-	-	-	-
Other stockholder equity	-	-4945.00000M	-5161.00000M	-4768.00000M
Property plant equipment	-	25149.00M	24488.00M	22768.00M
Total current assets	43516.00M	38782.00M	32168.00M	35722.00M
Long term investments	956.00M	-	-	-
Net tangible assets	-	-	-	-
Short term investments	0.00000M	447.00M	252.00M	498.00M
Net receivables	11775.00M	10278.00M	10349.00M	9450.00M
Long term debt	46750.00M	34462.00M	33683.00M	28745.00M
Inventory	6658.00M	6109.00M	6358.00M	5911.00M
Accounts payable	4404.00M	-	-	-
Total permanent equity	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-
Accumulated other comprehensive income	-	-	-	-
Additional paid in capital	-	-	-	-
Common stock total equity	-	-	-	-
Preferred stock total equity	-	-	-	-
Retained earnings total equity	-	-	-	-
Treasury stock	-	-	-	-
Accumulated amortization	-	-	-	-
Non currrent assets other	18818.00M	-	-	-
Deferred long term asset charges	-	-	-	-
Non current assets total	93350.00M	-	-	-
Capital lease obligations	-	-	-	-
Long term debt total	-	34462.00M	33683.00M	28745.00M

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Type	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Investments	471.00M	-	-	-
Change to liabilities	-	-	-	-
Total cashflows from investing activities	-	-7734.00000M	-14083.00000M	-4960.00000M
Net borrowings	11377.00M	-	-	-
Total cash from financing activities	-1922.00000M	-7032.00000M	-4810.00000M	-9119.00000M
Change to operating activities	-	-	-	-
Net income	18254.00M	17133.00M	377.00M	14526.00M
Change in cash	1372.00M	6409.00M	-5864.00000M	4606.00M
Begin period cash flow	13318.00M	-	-	-
End period cash flow	14690.00M	-	-	-
Total cash from operating activities	16472.00M	21468.00M	13006.00M	19095.00M
Issuance of capital stock	-	-	-	-
Depreciation	5838.00M	2104.00M	1828.00M	1824.00M
Other cashflows from investing activities	-	-4362.00000M	-10220.00000M	-572.00000M
Dividends paid	-8176.00000M	7840.00M	7445.00M	7012.00M
Change to inventory	-1180.00000M	-	-	-
Change to account receivables	-1090.00000M	-	-	-
Sale purchase of stock	-5084.00000M	-1129.00000M	-1221.00000M	384.00M
Other cashflows from financing activities	-	-372.00000M	-328.00000M	-240.00000M
Change to netincome	-	-	-	-
Capital expenditures	4112.00M	3372.00M	3863.00M	4388.00M
Change receivables	-	-	-	-
Cash flows other operating	-	-	-	-
Exchange rate changes	-	-	-	-
Cash and cash equivalents changes	-	-	-	-
Change in working capital	-6976.00000M	-3667.00000M	-2205.00000M	-2782.00000M
Stock based compensation	820.00M	-	-	-
Other non cash items	511.00M	-	-	-
Free cash flow	12360.00M	-	-	-

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company	Change (CAD)	Price (CAD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)	Enterprise Value to EBITDA (x)
MRK Merck CDR (CAD Hedged)	0.16 0.62%	25.84	15.70	22.32	4.40	5.36	4.81	11.07
NOVO Novo Nordisk CDR (CAD Hedged)	0.70 3.68%	19.70	3.31	3.54	1.10	1.74	3.88	7.66
AMGN Amgen CDR (CAD Hedged)	0.24 0.95%	25.54	24.19	15.65	5.06	21.36	6.30	13.69
GILD Gilead Sciences CDR (CAD Hedged)	-0.25 0.98%	25.30	19.51	15.04	5.62	7.21	6.14	13.31
SNY Sanofi CDR (CAD Hedged)	0.12 0.64%	18.92	3.25	1.53	0.34	0.22	2.33	8.73

Reports Covered

View All

Profile

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Merck CDR (CAD Hedged)

126 East Lincoln Avenue, Rahway, NJ, United States, 07065

908 740 4000
https://www.merck.com
Employees : 73000

Key Executives

Name	Title	Year Born
Mr. Robert M. Davis J.D.	Chairman, President & CEO	1967
Ms. Caroline A. Litchfield	Executive VP & CFO	1969
Ms. Betty D. Larson	Executive VP & Chief Human Resources Officer	1976
Mr. Richard R. DeLuca Jr.	Executive VP & President of Merck Animal Health	1963
Dr. Dean Y. Li M.D., Ph.D.	Executive VP & President of Merck Research Laboratories	1963
Mr. Dalton E. Smart III	Senior VP of Finance, Principal Accounting Officer & Global Controller	1967
Mr. David Michael Williams	Executive VP and Chief Information & Digital Officer	1969
Mr. Peter Dannenbaum	Vice President of Investor Relations	NA
Ms. Jennifer L. Zachary J.D.	Executive VP & General Counsel	1978
Mr. Sanat Chattopadhyay	Executive VP & President of Merck Manufacturing Division	1960

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.